Stephen K. Doberstein - Jun 3, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role
Director
Signature
/s/ Douglas W. Pagan, attorney-in-fact
Stock symbol
DRNA
Transactions as of
Jun 3, 2021
Transactions value $
$0
Form type
4
Date filed
6/7/2021, 09:32 PM
Next filing
Dec 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise +3.33K 3.33K Jun 3, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Restricted Stock Units Options Exercise $0 -3.33K -100% $0.00* 0 Jun 3, 2021 Common Stock 3.33K Direct F1, F2
transaction DRNA Restricted Stock Units Award $0 +3.33K $0.00 3.33K Jun 3, 2021 Common Stock 3.33K Direct F1, F3
transaction DRNA Director Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 3, 2021 Common Stock 15K $30.47 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2 Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.
F3 Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting.
F4 This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.